A private equity firm’s bid to combine the two biggest makers of medical-device coatings would harm competition for life-saving technologies, the Federal Trade Commission said at the start of a trial to block the deal https://t.co/GSbQiEZOvi ...

Core Insights - Microbot Medical Inc. (MBOT) has received a new U.S. patent that enhances the LIBERTY Endovascular Robotic System's applications, allowing for interchangeable tool-receiver units, thus broadening its use in endovascular procedures [1][8] - The new intellectual property (IP) is expected to increase the addressable market for the company from approximately 2.5 million to over six million annual endovascular procedures in the U.S., significantly expanding its market potential [2][8] - Following the patent announcement, MBOT's shares rose by 7.1%, with a year-to-date increase of 195.5%, contrasting with a 7% decline in the industry [3][7] Company Developments - The newly granted patent strengthens Microbot's long-term growth prospects by broadening the LIBERTY system's potential applications, enhancing its competitive differentiation and positioning for future partnerships and revenue opportunities once FDA clearance is obtained [4][8] - MBOT currently has a market capitalization of $140.7 million and projects an earnings growth of 56.2% for the current year [5] Product Overview - The LIBERTY system is designed as a single-use, fully disposable robotic platform for endovascular procedures, aimed at simplifying workflow and reducing risks associated with reprocessing [9][10] - Its modular architecture allows for configuration across various clinical applications, potentially increasing its relevance in a wider range of procedures than initially targeted [9][10]

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong fourth-quarter fiscal 2025 performance and ongoing studies [1][6][10] - The company's shares have seen a slight decline of 0.3% year-to-date, contrasting with a 7% decline in the industry and an 8.8% increase in the S&P 500 [1][2] Company Performance - AngioDynamics has a market capitalization of $358.8 million and projects a 50% growth over the next year, with earnings surpassing the Zacks Consensus Estimate in the last four quarters, averaging a surprise of 72.58% [2][3] - The fourth-quarter fiscal 2025 results showed a narrower adjusted loss per share and revenues exceeding expectations, indicating strong execution across both operating segments [11] Product and Market Dynamics - The NanoKnife product, which received FDA clearance and Breakthrough Device Designation, generated total revenues of $24.5 million in fiscal 2025, with fourth-quarter revenues of $7.2 million reflecting growth in disposable sales despite softer capital placements [3][4] - Recurring disposable sales grew by 9.6% for the year, providing a reliable revenue stream to offset variability in system placements [3] Clinical and Product Development - AngioDynamics is advancing a broad pipeline of clinical studies, including the AMBITION trial for Auryon and the RECOVER-AV trial for AlphaVac, aimed at enhancing its market position [7][8] - The NanoKnife's PRESERVE prostate trial has met primary endpoints, paving the way for reimbursement catalysts starting in 2026 [8] Financial Outlook - The company anticipates gross margins in the range of 53.5% to 55.5% for fiscal 2026, with adjusted EBITDA projected between $3.0 million and $8.0 million [13] - However, there has been a negative estimate revision trend for fiscal 2026, with the consensus estimate for loss per share expanding from 6 cents to 30 cents [14]

Core Insights - Medtronic (NYSE: MDT) reported its financial results before the market opened on Tuesday, showing a relatively solid performance despite a negative market reaction [1] - The analysis suggests that the reported numbers appear satisfactory upon closer examination, indicating potential undervaluation [1] Financial Performance - The financial results released by Medtronic indicate a stable performance, although specific figures and metrics were not detailed in the provided content [1] Market Reaction - Despite the solid financial results, the market's immediate reaction was negative, which may present an opportunity for investors who can identify value in the company's fundamentals [1]

Key Takeaways Teleflex Incorporated (TFX) recently announced the launch of the Barrigel rectal spacer in Japan, effective immediately following regulatory approval, insurance coverage acceptance and the issuance of appropriate use criteria by Japanese academic societies. Barrigel's commercialization in Japan marks a milestone in the company's global expansion strategy. Barrigel rectal spacer is the first and only hyaluronic rectal spacer that separates the prostate from the rectum to protect the latter duri ...

Milestones underscore Resmed's leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features R ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock price following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant stock price decline after announcing a revenue forecast cut on April 3, 2025, with shares dropping approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast reduction on July 8, 2025, led to another 38% decline in stock price, from $12.79 to $7.95, attributed to slower LAL utilization and adoption challenges [6].

MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). Advancing a broader fluid management platform: This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and practical implem ...

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially im ...

Core Insights - Catheter Precision, Inc. has initiated the LockeT Compare Study, enrolling its first three patients, aimed at evaluating the safety profile of the LockeT suture retention device [1][2] - The study will enroll up to 100 patients and compare the LockeT device with internal closure devices, focusing on reducing groin complications post-cardiac catheter procedures [2] - The LockeT device has shown clinical data indicating safety, effectiveness, and cost reduction without altering hospital practices [2][3] Company Overview - Catheter Precision is a U.S.-based medical device company dedicated to improving cardiac arrhythmia treatment through innovative technology and collaboration with physicians [4] - The LockeT device is a Class 1 device registered with the FDA and has received CE Mark approval, designed for wound closure after percutaneous venous punctures [3][4]